• 1
    McDowell JE, Mackie AE, Ventresca GP & Bye A. Pharmacokinetics and bioavailability of intra-nasal fluticasone in humans. Clin Drug Invest 1997; 1: 103105.
  • 2
    Harding SM. The human pharmacology of fluticasone propionate. Respir Med 1990; 84 (Suppl A): 2529.
  • 3
    Callejas SL, Biddlecombe RA, Jones AE, Joyce KB, Pereira AI & Pleasance S. Determination of the glucocorticoid fluticasone propionate in plasma by automated solid-phase extraction and liquid chromatography-tandem mass spectrometry. J Chromatogr B, Biomed Sci Applications 1998; 718: 243250.
  • 4
    Mackie AE, Ventresca GP, Fuller RW & Bye A. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996; 41: 539542.
  • 5
    Hardy JG, Lee SW & Wilson CG. Intra-nasal drug delivery by sprays and drops. J Pharm Pharmacol 1985; 37: 294297.
  • 6
    Bryant ML, Brown P, Gurevich N & McDougall IR. Comparison of the clearance of radiolabelled nose drops and nasal spray as mucosally delivered vaccine. Nuclear Med Comm 1999; 20: 171174.
  • 7
    Hensel R & Mullen ME. Pharmacokinetic report: an open label pharmacokinetic study of RG5029Y (triamcinolone acetonide) aqueous nasal spray and Nasacort nasal inhaler. Rhône-Poulenc Rorer, Protocol no. RG 5029Y-101 (Data on file), 1993.
  • 8
    Daley-Yates P, Price AC, Pereira A & Richards DH. Absolute bioavailability of beclomethasone dipropionate administered via the inhaled, intra-nasal and oral routes in man. Allergy 2000; 55 (Suppl 63): 952.
  • 9
    Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997; 91 (Suppl A): 2228.
  • 10
    Thorsson L, Borga O & Edsbacker S. Systemic availability of budesonide after nasal administration of three different formulations; pressurized aerosol, aqueous spray pump and powder. Br J Clin Pharmacol 1999; 47: 619624.DOI: 10.1046/j.1365-2125.1999.00956.x